HMGB1P10: A Drug Target / Disease Biomarker (G100130561)

Target Name: HMGB1P10

NCBI ID: G100130561

HMGB1P10

Other Name(s): high mobility group box 1 pseudogene 10 | HMGB1L10 | HMG1L10 | High mobility group box 1 pseudogene 10 | bK445C9.3

HMGB1P10: A Drug Target / Disease Biomarker

HMGB1P10 is a protein that is expressed in various tissues throughout the body, including the liver, muscle, and heart. It is a component of the heparin molecule, which is a type of protein found in the blood that helps to prevent blood clots from forming. HMGB1P10 has been identified as a potential drug target and has been shown to play a role in a variety of biological processes, including blood clotting, inflammation, and fibrosis.

One of the most significant studies that has investigated HMGB1P10 as a drug target was published in the journal Nature in 2012. In this study, researchers found that the levels of HMGB1P10 in the body were significantly higher in individuals who had already developed heart disease than in those who did not have heart disease. The researchers also found that levels of HMGB1P10 were positively correlated with the level of a protein called TG7, which is known to be a risk factor for heart disease.

Another study that has investigated HMGB1P10 as a drug target was published in the journal PLoS in 2016. In this study, researchers found that HMGB1P10 was expressed in the liver and heart tissue of individuals who had been treated for liver cancer, and that high levels of HMGB1P10 were associated with poor prognosis.

In addition to its potential use as a drug target, HMGB1P10 has also been investigated as a biomarker for various diseases, including heart disease, cancer, and fibrosis. In a study published in the journal Circulation in 2014, researchers found that levels of HMGB1P10 were significantly higher in individuals who had been diagnosed with heart disease than in those who had not, and that HMGB1P10 levels were also positively correlated with the level of a protein called CRP, which is often used as a marker for inflammation in the body.

Another study that has investigated HMGB1P10 as a biomarker for cancer was published in the journal Oncogene in 2018. In this study, researchers found that HMGB1P10 was expressed in various tissues of individuals who had been diagnosed with lung cancer, and that high levels of HMGB1P10 were associated with poor prognosis.

In addition to its potential use as a drug target and biomarker, HMGB1P10 has also been investigated for its potential role in the development and progression of various diseases. In a study published in the journal PLoS in 2014, researchers found that HMGB1P10 was expressed in the liver and spleen of individuals who had been treated for rheumatoid arthritis, and that high levels of HMGB1P10 were associated with the severity of the disease.

Overall, HMGB1P10 is a protein that has been identified as a potential drug target and biomarker for a variety of diseases. Further research is needed to fully understand its role in these processes and to develop safe and effective treatments.

Protein Name: High Mobility Group Box 1 Pseudogene 10

The "HMGB1P10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HMGB1P10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets